SFM
BCRX icon

Sphera Funds Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sphera Funds Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.22M Sell
422,051
-444,413
-51% -$4.02M 0.55% 63
2026
Q1 		$8.25M Buy
866,464
+28,575
+3% +$222K 1.31% 19
2025
Q4 		$6.54M Buy
+837,889
New +$6.06M 1.26% 28

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Sphera Funds Management's BCRX Position: Q2 2026 in Review

Sphera Funds Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 51% in Q2 2026, selling an estimated $4.02M and leaving 422,051 shares worth $4.22M. The position accounts for 0.55% of the portfolio, ranked #63.

Sphera Funds Management first reported a position in BCRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.25M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Sphera Funds Management held 422,051 shares of BioCryst Pharmaceuticals worth $4.22M as of Q2 2026.
  • Sphera Funds Management sold 444,413 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $4.02M.
  • BioCryst Pharmaceuticals made up 0.55% of Sphera Funds Management's portfolio in Q2 2026, its #63 holding.
  • Sphera Funds Management first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Sphera Funds Management's BioCryst Pharmaceuticals position peaked at $8.25M in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.